Fondazione Ricerca Traslazionale
Clinical trials sponsored by Fondazione Ricerca Traslazionale, explained in plain language.
-
New combo therapy hopes to extend life in tough lung cancer cases
Disease control OngoingThis study tests two new drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose first treatment stopped working. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of the combos or …
Phase: PHASE2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated May 26, 2026 07:54 UTC
-
New hope for lung cancer: combo therapy tested in phase 2 trial
Disease control OngoingThis study compares two treatments for people with advanced non-small-cell lung cancer that has spread. One group gets atezolizumab alone, the other gets atezolizumab plus bevacizumab. The goal is to see if the combination helps patients live longer and controls the cancer better…
Phase: PHASE2 • Sponsor: Fondazione Ricerca Traslazionale • Aim: Disease control
Last updated May 11, 2026 20:49 UTC